Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $97.32 USD
Change Today -3.58 / -3.55%
Volume 219.1K
LGND On Other Exchanges
Symbol
Exchange
NASDAQ GM
OTC US
Frankfurt
OTC US
OTC US
OTC US
As of 2:03 PM 07/1/15 All times are local (Market data is delayed by at least 15 minutes).

ligand pharmaceuticals (LGND) Snapshot

Open
$101.23
Previous Close
$100.90
Day High
$101.63
Day Low
$97.08
52 Week High
06/26/15 - $102.24
52 Week Low
10/9/14 - $41.99
Market Cap
1.9B
Average Volume 10 Days
527.1K
EPS TTM
$0.57
Shares Outstanding
19.7M
EX-Date
04/3/07
P/E TM
169.4x
Dividend
--
Dividend Yield
--
Current Stock Chart for LIGAND PHARMACEUTICALS (LGND)

ligand pharmaceuticals (LGND) Related Businessweek News

View More BusinessWeek News

ligand pharmaceuticals (LGND) Details

Ligand Pharmaceuticals Incorporated operates as a biotechnology company in the United States. The company’s commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis that is used for the treatment of multiple myeloma; bazedoxifene, which is used for the treatment of postmenopausal osteoporosis; and Captisol-enabled Noxafil-IV, a formulation of posaconazole for intravenous (IV) use. Its late-stage development programs include Captisol-enabled Melphalan IV, MK-8931 Beta-Secretase Inhibitor, Captisol-enabled SAGE-547, Sparsentan, Captisol-enabled Delafloxacin-IV, Captisol-enabled Carbamazepine-IV, IRAK4 Inhibitor Program, LTP Technology with Omega-3 Fatty Acids, Biologic Therapeutics Platform, Captisol-enabled Topiramate IV, Lasofoxifene, and Captisol-enabled Lamotrigine IV. The company’s internal product development programs include Glucagon Receptor Antagonist Program, Oral Human Granulocyte Colony Stimulating Factor Program, LTP Platform, Kinase Inhibitors, HepDirect HCV Inhibitor Program, and other programs. Its therapies in development portfolio addresses the unmet medical needs of patients for a range of diseases, including hepatitis, multiple myeloma, muscle wasting, Alzheimer’s disease, dyslipidemia, diabetes, anemia, epilepsy, focal segmental glomerulosclerosis, and osteoporosis. Ligand Pharmaceuticals Incorporated has alliances with GlaxoSmithKline, Amgen, Inc., Merck, Pfizer, Baxter International, and Eli Lilly and Co. The company was founded in 1987 and is headquartered in La Jolla, California.

19 Employees
Last Reported Date: 02/23/15
Founded in 1987

ligand pharmaceuticals (LGND) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: $510.2K
President and Chief Operating Officer
Total Annual Compensation: $375.4K
Vice President, General Counsel and Secretary
Total Annual Compensation: $288.9K
Compensation as of Fiscal Year 2014.

ligand pharmaceuticals (LGND) Key Developments

Ligand Pharmaceuticals Incorporated Announces FDA Approves Promacta for New Pediatric Chronic Immune Thrombocytopenia Indication

Ligand Pharmaceuticals Incorporated announced that the FDA has approved a supplemental New Drug Application (sNDA) for the use of Promacta (eltrombopag), a Novartis product, for the treatment of children six years and older with chronic immune thrombocytopenia (cITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Promacta was approved by the FDA in 2008 for use in adult patients with the same condition. Promacta was acquired by Novartis in March 2015 from GSK. Promacta was discovered as a result of research collaboration between GSK and Ligand Pharmaceuticals and developed by GSK. The approval of Promacta was based on data from two double-blind, placebo-controlled trials, including the large Phase 3 clinical trial in this patient population. Treatment with Promacta significantly increased and sustained platelet counts among some pediatric patients with cITP, and some patients taking concomitant ITP medications were able to reduce or discontinue their use of these medications, primarily corticosteroids. Promacta should be used only in those whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. Promacta is a once-daily oral thrombopoietin (TPO) receptor agonist that works by inducing stimulation and differentiation of megakaryocytes (large cells, found especially in bone marrow) from bone marrow stem cells to increase platelet production.

Ligand Pharmaceuticals Incorporated Announces Favorable Results from Phase 1B Trial with LGD-6972 in Type 2 Diabetes and Plans to Initiate Phase 2 Trial

Ligand Pharmaceuticals Incorporated announced results from a Phase 1b clinical trial with LGD-6972 that demonstrate favorable safety, tolerability and pharmacokinetics in normal healthy volunteers and in subjects with type 2 diabetes mellitus. The trial results also demonstrate a dose-dependent reduction of fasting plasma glucose. Glucagon receptor antagonists are the leading non-insulin mechanism in development for the treatment of type 2 diabetes. Based on earlier data and these latest results, Ligand believes LGD-6972 has best-in-class properties given its potency, preliminary effectiveness in lowering plasma glucose in patients with type 2 diabetes and its safety profile demonstrated in two Ligand-sponsored clinical trials. In this randomized, double-blind, placebo-controlled trial, LGD-6972 was administered in sequential increasing oral doses daily over two weeks to both healthy subjects and subjects with type 2 diabetes. A total of 48 subjects were enrolled in the trial. Highlights of the study include: LGD-6972 tested at 5mg, 10mg and 15mg was safe and well-tolerated with no clinically significant or dose-dependent changes in hematology, clinical chemistry or urinalysis panels, ECG or vital signs. There were no serious adverse events and no study discontinuations. All treatment-emergent adverse events were of mild or moderate severity (grade 1 or 2); Plasma levels increased linearly with LGD-6972 dosage, and the pharmacokinetic profiles were comparable between normal and type 2 diabetes subjects, supporting once-daily dosing; LGD-6972 lowered fasting plasma glucose in normal subjects and in subjects with type 2 diabetes. Glucose was reduced throughout the 14-day dosing period. Baseline adjusted glucose values showed dose-dependent effects of LGD-6972 in type 2 diabetic subjects with a maximal decrease of 60 mg/dL; 7 point glucose measurements were performed at baseline and Day 14 and illustrated that LGD-6972 decreased glucose throughout a 24-hour period in both fasting and post-prandial states; LGD-6972 is a highly potent and selective glucagon receptor antagonist and is a promising agent for the treatment of type 2 diabetes. The company is preparing to initiate a Phase 2 trial with LGD-6972 in 2016 with the goal to establish additional safety and efficacy for the program in 12 consecutive weeks of dosing in subjects with type 2 diabetes. Approximately 100 subjects will be enrolled in this randomized, double-blind, multicenter trial.

Ligand Pharmaceuticals Incorporated - Special Call

To present the results from the LGD-6972 Phase 1b Multiple-Ascending Dose trial

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LGND:US $97.32 USD -3.58

LGND Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $49.23 USD +0.15
Allergan plc $305.05 USD +1.59
Johnson & Johnson $98.05 USD +0.59
Pfizer Inc $33.73 USD +0.20
Valeant Pharmaceuticals International Inc C$277.47 CAD +4.61
View Industry Companies
 

Industry Analysis

LGND

Industry Average

Valuation LGND Industry Range
Price/Earnings 100.0x
Price/Sales 31.3x
Price/Book 56.4x
Price/Cash Flow 185.8x
TEV/Sales 25.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LIGAND PHARMACEUTICALS, please visit www.ligand.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.